Oruka Therapeutics GC Paul Quinlan sells $5.64m stock

In a notable transaction on August 14, 2026, Paul T. Quinlan, General Counsel at Oruka Therapeutics, sold 52,000 shares of the company's common stock, generating approximately $5.64 million in proceeds. The shares were sold at a range of $106.0504 to $111.1378 per share. The current stock price of $111.04 is just 1% below its 52-week high of $111.37, following an impressive 622% return over the past year.

UBS raised its price target for Oruka Therapeutics to $130, while H.C. Wainwright maintained a Buy rating with a $120 target. Piper Sandler affirmed an Overweight rating with a $180 price target. Despite the company's positive financial news, InvestingPro analysis suggests that Oruka Therapeutics is currently overvalued.